• Overactive bladder;
  • tolterodine;
  • bothersome symptoms;
  • urgency;
  • urgency urinary incontinence;
  • patient-reported outcomes;
  • OAB-q;
  • AUA-SI;
  • PPBC


We evaluated the effect of tolterodine extended release (ER) on patient- and clinician-reported outcomes in a primary care setting. Patients had overactive bladder (OAB) symptoms for ≥3 months and were at least moderately bothered by their most bothersome symptom, as indicated on the patient-completed OAB Bother Rating Scale. Patients completed the Overactive Bladder Questionnaire (OAB-q), American Urological Association Symptom Index (AUA-SI), and Patient Perception of Bladder Condition at each visit; investigators completed the Clinical Global Impression-Improvement at week 12. By week 12, there were statistically significant and clinically meaningful decreases on the OAB-q and AUA-SI total and subscale scores (p < 0.0001). Seventy-nine per cent of patients experienced some improvement in their overall bladder condition. Physicians reported that 68% of patients were ‘much improved’ or ‘very much improved’. For symptom-defined conditions, patient-reported outcomes are a valuable means for determining responses to treatment.